Estrella Immunopharma, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. Market Information Our common stock and warrants trade on the Nasdaq Capital Market under the symbols “ESLA” and “ESLAW,” respectively, since October 2, 2023. Holders As of December 31, 2025, there were 19 registered holders of record of our Common Stock and one holder of record of our warrants. The single record holder for our warrants is Cede & Co., a nominee for The Depository Trust Company, which holds all of our outstanding warrants in “street name”. These figures do not include the number of beneficial owners whose shares or warrants are held in “street name” through banks or broker-dealers. Dividends We have not paid any cash dividends to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition. The payment of any cash dividends will be within the discretion of the Board at such time. Unregistered Sales of Equity Securities All sales of unregistered securities during the fiscal year ended December 31, 2025, were previously disclosed in our quarterly reports on Form 10-Q or current reports on Form 8-K, as applicable. Issuer Purchases of Common Stock None. Securities Authorized for Issuance Under Equity Compensation Plans Equity Compensation Plan Information Plan category Number of securities to be issued upon exercise of outstanding options, warrants and rights (a) Weighted-average exercise price of outstanding options, warrants and rights (b) Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (c) Equity compensation plans approved by security holders 3,600,000 $ 0.815 3,781,860 Equity compensation plans not approved by security holders None — None Total 3,600,000 $ 0.815 3,781,860 Item 6. [Reserved] 88